{
  "ticker": "EXEL",
  "company_name": "Exelixis",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04220229",
      "title": "Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities",
      "start_date": "2020-06-01",
      "completion_date": "2024-10-31",
      "enrollment": 0,
      "sponsor": "University of Washington"
    },
    {
      "nct_id": "NCT06902376",
      "title": "XL092 and Cemiplimab in BRAF WT Thyroid Cancer",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors",
      "start_date": "2025-06-03",
      "completion_date": "2028-08-31",
      "enrollment": 0,
      "sponsor": "UNC Lineberger Comprehensive Cancer Center"
    },
    {
      "nct_id": "NCT01811212",
      "title": "Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Follicular Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Follicular Carcinoma, Stage II Thyroid Gland Papillary Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IVA Thyroid Gland Follicular Carcinoma, Stage IVA Thyroid Gland Papillary Carcinoma, Stage IVB Thyroid Gland Follicular Carcinoma, Stage IVB Thyroid Gland Papillary Carcinoma, Stage IVC Thyroid Gland Follicular Carcinoma, Stage IVC Thyroid Gland Papillary Carcinoma, Tall Cell Variant Thyroid Gland Papillary Carcinoma, Thyroid Gland Oncocytic Follicular Carcinoma",
      "start_date": "2013-05-08",
      "completion_date": "2017-10-09",
      "enrollment": 0,
      "sponsor": "National Cancer Institute (NCI)"
    },
    {
      "nct_id": "NCT03539822",
      "title": "Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer",
      "start_date": "2018-10-22",
      "completion_date": "2028-01-31",
      "enrollment": 0,
      "sponsor": "Anwaar Saeed"
    },
    {
      "nct_id": "NCT01630590",
      "title": "Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Prostate Cancer",
      "start_date": "2014-01-08",
      "completion_date": "2021-04-06",
      "enrollment": 0,
      "sponsor": "M.D. Anderson Cancer Center"
    },
    {
      "nct_id": "NCT04477512",
      "title": "Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Metastatic Hormone Refractory Prostate Cancer",
      "start_date": "2021-02-19",
      "completion_date": "2025-09-10",
      "enrollment": 0,
      "sponsor": "Washington University School of Medicine"
    },
    {
      "nct_id": "NCT06835972",
      "title": "A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma",
      "start_date": "2025-02-14",
      "completion_date": "2027-02",
      "enrollment": 0,
      "sponsor": "Memorial Sloan Kettering Cancer Center"
    },
    {
      "nct_id": "NCT06082167",
      "title": "Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Head and Neck Squamous Cell Carcinoma",
      "start_date": "2024-06-07",
      "completion_date": "2029-03",
      "enrollment": 0,
      "sponsor": "Exelixis"
    },
    {
      "nct_id": "NCT07227402",
      "title": "A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Renal Cell Carcinoma",
      "start_date": "2025-11-26",
      "completion_date": "2032-02-27",
      "enrollment": 0,
      "sponsor": "Merck Sharp & Dohme LLC"
    },
    {
      "nct_id": "NCT00670189",
      "title": "A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hedgehog Pathway, Smoothened, Basal Cell Carcinoma (BCC), Basal Cell Nevoid Syndrome (BCNS)",
      "start_date": "2008-07",
      "completion_date": "2014-05",
      "enrollment": 0,
      "sponsor": "Bristol-Myers Squibb"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1, PHASE2": 4,
      "PHASE1": 19,
      "PHASE2": 21,
      "PHASE2, PHASE3": 2,
      "PHASE3": 4
    },
    "by_status": {
      "TERMINATED": 8,
      "RECRUITING": 11,
      "COMPLETED": 18,
      "ACTIVE_NOT_RECRUITING": 8,
      "NOT_YET_RECRUITING": 2,
      "WITHDRAWN": 2,
      "SUSPENDED": 1
    },
    "active_trials": 19,
    "completed_trials": 18,
    "conditions": [
      "Advanced Cancer, Various, NOS",
      "Advanced Urothelial Carcinoma",
      "Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors",
      "Bone Sarcomas",
      "Breast Cancer",
      "Cancer, Lymphoma",
      "Cancer, Non-small-cell Lung Cancer, Breast Cancer",
      "Cancer, Solid Tumors",
      "Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors",
      "Carcinoma, Non-small Cell Lung Cancer",
      "Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive",
      "Clear Cell Renal Cell Carcinoma",
      "Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer, Rectal Cancer, Rectal Adenocarcinoma, Colorectal Cancer",
      "Colorectal Cancer",
      "Differentiated Thyroid Cancer",
      "Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer",
      "Glioblastoma Multiforme",
      "Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma",
      "Head and Neck Squamous Cell Carcinoma",
      "Hedgehog Pathway, Smoothened, Basal Cell Carcinoma (BCC), Basal Cell Nevoid Syndrome (BCNS)",
      "Hepatic Impairment, Moderate Hepatic Impairment",
      "Kidney Cancer, Renal Cell Carcinoma",
      "Melanoma",
      "Merkel Cell Carcinoma, Skin Cancer",
      "Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Unresectable Head and Neck Squamous Cell Carcinoma",
      "Metastatic Hormone Refractory Prostate Cancer",
      "Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma",
      "Metastatic Soft-tissue Sarcoma",
      "Myeloproliferative Disorders, Myelofibrosis, Polycythemia Vera, Thrombocythemia, Essential",
      "Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer",
      "Neuroblastoma, Sarcoma",
      "Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain",
      "Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon, Upper Aerodigestive Tract Carcinoma",
      "Pancreatic Cancer",
      "Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)",
      "Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma, Renal Cell Carcinoma, Unresectable Advanced Renal Cell Carcinoma, Metastatic Ncc Renal Cell Carcinoma",
      "Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Follicular Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Follicular Carcinoma, Stage II Thyroid Gland Papillary Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IVA Thyroid Gland Follicular Carcinoma, Stage IVA Thyroid Gland Papillary Carcinoma, Stage IVB Thyroid Gland Follicular Carcinoma, Stage IVB Thyroid Gland Papillary Carcinoma, Stage IVC Thyroid Gland Follicular Carcinoma, Stage IVC Thyroid Gland Papillary Carcinoma, Tall Cell Variant Thyroid Gland Papillary Carcinoma, Thyroid Gland Oncocytic Follicular Carcinoma",
      "Prostate Cancer",
      "Prostate Cancer, Prostate Cancer Adenocarcinoma, Non-Metastatic",
      "Renal Cell Carcinoma",
      "Sarcoma of the Extremity, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities",
      "Solid Tumor",
      "Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor",
      "Solid Tumors, Cancer",
      "Solid Tumors, Cancer, NSCLC",
      "Stomach Neoplasms, Esophageal Neoplasms",
      "Thyroid Cancer"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:03:17.926205",
    "search_query": "Exelixis",
    "url": "https://clinicaltrials.gov/search?term=Exelixis"
  }
}